GnRH receptor
12 drugs Oncology
3
approved indications
12
Approved Drugs
8
Companies
7
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 12 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (7 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
AbbVie 3 drugs
SUMITOMO PHARMA AM 2 drugs
TOLMAR 2 drugs
By Therapeutic Area
Oncology 8 drugs
Other 4 drugs
Drugs by Company PRO
AbbVie 3 drugs
TOLMAR 2 drugs
INVAGEN PHARMS 1 drug
AZURITY 1 drug
VERITY 1 drug
ENDO OPERATIONS 1 drug
FERRING 1 drug
By Therapeutic Area
Oncology 8 drugs
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION, ELIGARD KIT, TRIPTODUR KIT, TRELSTAR +4 more
Other 4 drugs
LUPRON DEPOT, MYFEMBREE, SUPPRELIN LA, ORILISSA
Indications Treated
Prostate CancerEndometriosisUterine LeiomyomataAnemiaCentral Precocious PubertyHeavy Menstrual BleedingUterine Leiomyoma
All Drugs Targeting GnRH receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| LUPRON DEPOT | AbbVie | 1989 | 3 | |
| MYFEMBREE | SUMITOMO PHARMA AM | 2021 | 3 | |
| LEUPROLIDE ACETATE FOR DEPOT SUSPENSION | INVAGEN PHARMS | 2018 | 1 | Oncology |
| ELIGARD KIT | TOLMAR | 2002 | 1 | Oncology |
| TRIPTODUR KIT | AZURITY | 2017 | 1 | Oncology |
| TRELSTAR | VERITY | 2000 | 1 | Oncology |
| LUPRON DEPOT-PED KIT | AbbVie | 1993 | 1 | Oncology |
| SUPPRELIN LA | ENDO OPERATIONS | 2007 | 1 | |
| ORGOVYX | SUMITOMO PHARMA AM | 2020 | 1 | Oncology |
| ORILISSA | AbbVie | 2018 | 1 | |
| FENSOLVI KIT | TOLMAR | 2020 | 1 | Oncology |
| FIRMAGON | FERRING | 2008 | 1 | Oncology |